ArmaGen reports preliminary evidence of cognitive improvement in children with MPS I treated with AGT-181 

News

Microscope icon representing research and treatment

ArmaGen reports preliminary evidence of cognitive improvement in children with MPS I treated with AGT-181 

Initial Results from Phase 2 Proof-of-Concept Trial Presented at 2017 WORLDSymposium Findings Demonstrate Ability of ArmaGen’s Proprietary Drug Delivery Technology to Transport Biopharmaceuticals Across the Blood-Brain Barrier ArmaGen, Inc., a privately held biotechnology company focused on developing groundbreaking therapies to

Howletts logo

Join us for a fun-filled day at Howletts Zoo

The MPS Society are offering a fun-filled day at Howletts – the Aspinall wild animal park on Friday 7th April 2017. From only £10 for a family of four this will be a great day out at Kent’s original wildlife park. With over

MPS Society logo

Press release – NICE condemns to death up to three babies each year in England

NICE the drug decision making body have announced their final decision  today, Wednesday 15 February 2017, not to recommend Kanuma (Sebelipase alfa), the treatment for  individuals suffering from Lysosomal Acid Lipase Deficiency (LAL D). Kanuma was given fast track approval

7 ways to say I love you without breaking the bank

Valentine’s Day can be expensive Here are 7 ways to say “I love you” without breaking the bank 1. Send a Valentine’s e-card – fast, efficient and environmentally friendly or make your own card. 2. Forfeit the Food – why not give

FDA logo

FDA permits marketing of first newborn screening system MPS I and Fabry

The U.S. Food and Drug Administration have permitted marketing of the Seeker System for the screening of four, rare Lysosomal Storage Disorders (LSDs) in newborns. The Seeker system is designed to detect Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher and Fabry.